Prevalence and clinical characteristics of a high cardiac output state in patients with multiple myeloma

McBride, Wade; Jackman, John D.; Grayburn, Paul A.

doi:10.1016/0002-9343(90)90092-r

Cited by 30 publications

(24 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, more than 20% of the mortality is due to alterations in heart function. Indeed, McBride and collaborators [35] observed that more than 50% of multiple myeloma patients suffered cardiac failure during the neoplastic process. Data from our own laboratory also indicate that tumours implanted in experimental animals resulted in a decrease of the heart weight [20].…”

Section: Resultsmentioning

confidence: 99%

Theophylline is able to partially revert cachexia in tumour-bearing rats

et al. 2012

View full text Add to dashboard Cite

Background and aimsThe aim of the present investigation was to examine the anti-wasting effects of theophylline (a methylxantine present in tea leaves) on a rat model of cancer cachexia.MethodsThe in vitro effects of the nutraceuticals on proteolysis were examined on muscle cell cultures submitted to hyperthermia. Individual muscle weights, muscle gene expression, body composition and cardiac function were measured in rats bearing the Yoshida AH-130 ascites hepatoma, following theophylline treatment.ResultsTheophylline treatment inhibited proteolysis in C2C12 cell line and resulted in an anti-proteolytic effect on muscle tissue (soleus and heart), which was associated with a decrease in circulating TNF-alpha levels and with a decreased proteolytic systems gene expression. Treatment with the nutraceutical also resulted in an improvement in body composition and cardiac function.ConclusionTheophylline - alone or in combination with drugs - may be a candidate molecule for the treatment of cancer cachexia.

show abstract

Section: Resultsmentioning

confidence: 99%

Theophylline is able to partially revert cachexia in tumour-bearing rats

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Since VEGF is a multifunctional cytokine that stimulates vasodilation, vascular hyperpermeability, and angiogenesis, and was reported to stimulate endothelial nitric oxide production (7), we suspect that VEGFmay have decreased systemic vascular resistance in our patient resulting in the development of a high cardiac output state, which was followed by high-output heart failure. Onthe other hand, multiple myelomawas also reported to cause a high cardiac output state (8,9). Since both multiple myelomaand Crow-Fukase syndrome exhibit plasma cell dyscrasia, and since cytokines are suspected in the pathogenesis of both of these diseases (10, 1 1), we suspect that there may be a commonmechanism for the high cardiac output state in both multiple myelomaand Crow-Fukase syndrome, which might be mediated by VEGF.Further studies are necessary to clarify these points.…”

Section: Discussionmentioning

confidence: 97%

Crow-Fukase Syndrome Associated with High-Output Heart Failure.

et al. 2002

View full text Add to dashboard Cite

A 64-year-old womanwas admitted with systemic edema and exertional dyspnea. High-output heart failure was diagnosed by right heart catheterization and she was treated with diuretics. After 3 weeks, her symptoms disappeared but a high cardiac output state persisted. A diagnosis of Crow-Fukasesyndromewas madebased on the presence of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes. Her serum vascular endothelial growth factor (VEGF) level was markedly elevated after recovery from heart failure. Wesuspect that an elevated VEGFlevel and a high cardiac output state mayplay a role in the pathogenesis of heart failure in Crow-Fukase syndrome. (Internal Medicine 41: 638-641, 2002)

show abstract

“…The prevalence of HOCF among patients with multiple myeloma may be greater than currently accepted. McBride et al [11] reviewed 36 patients with multiple myeloma, without cardiac specific inclusion criteria, and documented HOCF among eight (23.5%) evaluable patients. On multivariate analysis, degree of bone marrow involvement was the strongest predictor of HOCF (with p ¼ 0.001).…”

Section: (Received 29 November 2007; Accepted 11 December 2007)mentioning

confidence: 99%